Clinuvel Pharmaceuticals (ASX:CUV) Debt-to-Asset : 0.01 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Debt-to-Asset?

Clinuvel Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.36 Mil. Clinuvel Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.71 Mil. Clinuvel Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$211.68 Mil. Clinuvel Pharmaceuticals's debt to asset for the quarter that ended in Dec. 2023 was 0.01.

Clinuvel Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Debt-to-Asset Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.02

0.01

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Competitive Comparison of Clinuvel Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Debt-to-Asset falls into.

Clinuvel Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Clinuvel Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.301	+	0.699)	/	193.714
	=	0.01

Clinuvel Pharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.356	+	0.713)	/	211.681
	=	0.01

Clinuvel Pharmaceuticals (ASX:CUV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Clinuvel Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (ASX:CUV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (ASX:CUV) Headlines

No Headlines